Clinical Trial

CAR T Cells to Target GD2 for DMG

Study acronym: CARMIGO
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of generating the ATIMP, the safety and tolerability of the GD2CAR T-cell therapy and how effectively GD2CAR T-cells engraft, expand and persist following administration in patients with DMG.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12 -> 2027-08 2026-08-12
minor Completion pushed: 2039-12 -> 2042-08 2026-08-12
Trial Details
NCT Number NCT05544526
Lead Sponsor University College, London
Conditions Diffuse Midline Glioma, H3 K27M-Mutant
Enrollment 12 participants
Start Date 2023-08-15
Primary Completion 2027-08 (estimated)
Study Completion 2042-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-11